Industry-Supported Symposia Cover Gamut
Industry-supported symposia (ISS) are part of the scientific program of APA's annual meeting and are accredited for Category 1 CME credit. These symposia are submitted by APA members and are peer reviewed and selected by the Scientific Program Committee. They are supported by educational grants from pharmaceutical and medical-equipment companies and follow all standards and guidelines for commercial support set forth by the Accreditation Council for Continuing Medical Education.
As part of the APA screening process, the syllabi for the ISS presentations are peer reviewed for balance in advance by APA member volunteers. Feedback is given to presenters to change slides that are seen as biased toward a medication or treatment. Moreover, seating for meeting participants who do not wish to partake of pre-symposia meals are available, along with handouts.
All ISS are evaluated by participants and resident monitors for balance and quality. These evaluations are reviewed by the Scientific Program Committee and the Committee on Commercial Support.
All ISS are available as Webcasts after the meeting at no charge. They can be accessed at the Annual Meeting Online section of APA's Web site at<www.psych.org> under “Education and Career Development.” Symposia handouts are also posted.
Below are the ISS that will be offered at APA's 2008 annual meeting. The schedule was not available at the time Psychiatric News produced its annual meeting issue (February 1). Because of possible scheduling changes, registrants are advised to check the program book on site at the meeting.
SATURDAY, MAY 3
12:30 p.m.
ISS 1
Psychiatric Issues in Women Through the Adult Life-Cycle
Ballroom A/B, Level 3, Convention Center
Supporter: Wyeth Pharmaceuticals
ISS 2
Comprehensive Care for the Long-Term Patient With Schizophrenia: Treating the Whole Patient
Grand Ballroom, Ballroom Level, Renaissance
Supporter: Pfizer Inc.
ISS 3
Recent Advances in Alzheimer's Disease: Expert Opinions on Current and Emerging Theories
Independence Ballroom,Level 5B, Grand Hyatt
Supporter: Forest Laboratories Inc.
6:30 p.m.
ISS 4
Fibromyalgia: Diagnostic Advances and Emerging Pharmacologic Therapies for a Complex, Multidimensional Disorder
Ballroom A/B, Level 3, Convention Center
Supporter: Eli Lilly and Company
ISS 5
Addressing Unmet Clinical Needs in Severe Depression: Translating the Latest Findings
Grand Ballroom, Ballroom Level, Renaissance
Supporter: Sanofi-Aventis
ISS 6
Pediatric and Adolescent ADHD: Back to the Basics
Independence Ballroom, Level 5B, Grand Hyatt
Supporter: Abbott Laboratories
SUNDAY, MAY 4
8 a.m.
ISS 7
Treating Patients Early: Updates on the Controversy
Ballroom A/B, Level 3, Convention Center
Supporter: AstraZeneca Pharmaceuticals
ISS 8
Advances in Neuroimaging and Genetics in ADHD
Grand Ballroom, Ballroom Level, Renaissance
Supporter: McNeil Pediatrics/Ortho-McNeil Janssen Scientific Affairs, LLC.
ISS 9
Recent Advances in the Diagnosis and Treatment of Fibromyalgia
Independence Ballroom, Level 5B, Grand Hyatt
Supporter: Pfizer Inc.
1:30 p.m.
ISS 10
Unlocking the Combination: Moving Toward a Better Understanding of Major Depressive Disorder
Ballroom A/B, Level 3, Convention Center
Supporter: Wyeth Pharmaceuticals
ISS 11
Genetics in Psychiatry: Opportunities and Obstacles in Schizophrenia
Grand Ballroom, Ballroom Level, Renaissance
Supporter: Vanda Pharmaceuticals
ISS 12
Treatment of Children and Adolescents With Psychiatric Disorders: The Rising Use of Antipsychotics
Independence Ballroom, Grand Hyatt Hotel
Supporter: Bristol-Myers Squibb Company and Otsuka America Pharmaceuticals
7 p.m.
ISS 13
Tangled Up in Blue: Optimizing Treatment of Depression in the Presence of Comorbidities
Ballroom A/B, Level 3, Convention Center
Supporter: Eli Lilly and Company
ISS 14
Mood Disturbance in Younger and Mid-Life Women: Defining Treatment Strategies
Grand Ballroom, Ballroom Level, Renaissance
Supporter: Forest Laboratories, Inc.
ISS 15
Using a Chronic Disease Model When Managing Patients With Severe Mental Illness
Independence Ballroom, Level 5B, Grand Hyatt
Supporter: Eli Lilly and Company
MONDAY/TUESDAY, May 5, 6
7 a.m.
ISS 16
Are Cognition, Sleep and Wake Disorders Caused by too Much Arousal, too Little Arousal or Both?
Ballroom A/B, Level 3, Convention Center
Supporter: Takeda Pharmaceuticals
ISS 17
Understanding Bipolar Disorder: Quality and Clinical Conundrums
Grand Ballroom, Ballroom Level, Renaissance
Supporter: Pfizer Inc.
ISS 18
Genetics, Brain Imaging, and Pharmacology: Clinical Implications for Therapeutic Choices in Schizophrenia and Bipolar Disorder
Independence Ballroom A-E, Level 5B, Grand Hyatt
Supporter: Organon Pharmaceuticals USA Inc.
MONDAY, MAY 5
7 p.m.
ISS 19
Is Recovery Attainable in Schizophrenia? Biologic, Pharmacologic, and Psychologic Perspectives
Ballroom A/B, Level 3, Convention Center
Supporter: AstraZeneca Pharmaceuticals
ISS 20
Novel and Current Antidepressants: State-of-the-Art Management of Depression
Grand Ballroom, Ballroom Level, Renaissance
Supporter: Novartis Pharmaceuticals Corporation
ISS 21
Sleep and Sleep Disorders Across the Life Cycle: What Psychiatrists Need to Know
Independence Ballroom, Level 5B, Grand Hyatt
Supporter: Sepracor, Inc.
TUESDAY, MAY 6
7 p.m.
ISS 22
Organizing the Evidence: Obsessive Compulsive Related Disorders: New Perspectives Toward DSM-V
Ballroom A/B, Level 3, Convention Center
Supporter: Jazz Pharmaceuticals, Inc.
ISS 23
Understanding the Endocannabinoid System: Key Links Between Mind, Body, and Neuropsychiatry
Grand Ballroom, Ballroom Level, Renaissance
Supporter: Sanofi-Aventis
Schizophrenia: The Complexity of Real-World Care
Independence Ballroom A-E, Level 5B, Grand Hyatt
Supporter: Janssen Pharmaceutica and Research
WEDNESDAY, MAY 7
7 p.m.
ISS 26
Novel Perspectives Towards a Better Understanding of Major Depressive Disorder
Ballroom A/B, Level 3, Convention Center
Supporter: Bristol-Myers Squibb Company and Otsuka America Pharmaceuticals
ISS 27
Individualizing Treatment Plans for Total Health in Patients With Bipolar Disorder
Ballroom C, Level 3, Convention Center
Supporter: Organon Pharmaceuticals USA Inc.
ISS 28
Advancing Science and Practice in the Management of ADHD From Child to Adult: An Interactive Case Presentation
Grand Ballroom, Ballroom Level, Renaissance
Supporter: Shire US, Inc.
ISS 29
Beyond Pain to “Fibrofog” and Sleep Impairments: Implications for Neurocircuitry and Treatments in Fibromyalgia
Independence Ballroom A-E, Level 5B, Grand Hyatt
Supporter: Pfizer Inc.
